Pharmaceutical marketing, research and development company Breckenridge Pharmaceutical has signed a deal to acquire certain assets of Pernix Therapeutics' subsidiary, Cypress Pharmaceuticals, for $30m. The assets included in the agreement ...
Pernix Therapeutics Holdings, a specialty pharmaceutical company, is planning to deploy CDC Software's Ross Enterprise. Ross Enterprise will help Pernix automate and integrate key business processes, and automate certain validation ...
Tags: Pernix Therapeutics Holdings, Ross Enterprise, CDC Software
Pernix Therapeutics has entered into a definitive agreement to acquire Cypress Pharmaceuticals and Hawthorn Pharmaceuticals in Madison, Mississippi, US. Hawthorn offers branded drugs including allergy, respiratory, iron deficiency, ...
Tags: Pernix Therapeutics, Cypress Pharmaceuticals, Hawthorn Pharmaceuticals
Pernix Therapeutics Holdings has reported a net loss of $270,342, or $0.01 per share, for the third quarter ended 30 September 2012 compared to a net income of $1.99m, or $0.08 per share, for thesame period in 2011. Net sales for the ...
Pernix Therapeutics Holdings has launched Omeclamox-Pak, a ten-day therapy, to eradicate Helicobacter pylori (H. pylori) in adult patients. Omeclamox-Pak is composed of omeprazole delayed-release capsules (20mg), clarithromycin tablets ...
Tags: Omeclamox-Pak, H.pylori, ten-day therapy
Pernix Therapeutics, a specialty pharmaceutical company, has announced the availability of Omeclamox-Pak to treat Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in ...
Tags: Oral Therapy, Omeclamox-Pak, H.pylori